Ignite Creation Date:
2024-05-06 @ 1:58 AM
Last Modification Date:
2024-10-26 @ 11:12 AM
Study NCT ID:
NCT01945021
Status:
COMPLETED
Last Update Posted:
2021-02-21
First Post:
2013-09-05
Brief Title:
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive ALK Negative Advanced NSCLC
Sponsor:
Pfizer
Organization:
Pfizer
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Crizotinib |
| Non Small Cell Lung Cancer |
| ROS1 Proto Oncogene |
Keywords:
| Name | View |
|---|---|
| North East Asian | View |
| Non small cell lung cancer | View |
| NSCLC | View |
| ROS1 | View |
| ROS1 positive | View |
| ROS1 proto oncogene | View |
| c ros tyrosine kinases | View |
| ROS1 positive NSCLC | View |
| ROS1 lung cancer | View |
| ALK negative | View |
| Lung Carcinoma | View |
| Neoplasm | View |
| Crizotinib | View |
| Xalkori | View |
| Previously treated or untreated | View |